Caution with New Oral Hepatitis C Drugs
Vicente Soriano 1, Isabella Esposito 2
1 UNIR Health Sciences School and Medical Center, Universidad Internacional de La Rioja, Madrid, Spain; 2 NULL
*Correspondence: Isabella Esposito, Email not available
Abstract
The hepatitis C field is living a revolution following the introduction of all-oral therapies that can cure most patients with short courses of direct-acting antiviral (DAA) combinations. Given that chronic hepatitis C affects globally around 20% of HIV persons, major attention has been focused on the HIV/HCV-coinfected population. Current evidence suggests that these patients depict cure rates of over 90%, similar to HCV-monoinfected individuals (Sulkowski, et al. JAMA. 2014; 312:353-61). Accordingly, current guidelines for hepatitis C therapy no longer separate mono- and coinfected subjects.
